Re-breathing of Inert Gas for Measurement of Cardiac Output and Validation of Intra-Cardiac Shunt — CPB 0714 | AETNA Coverage Update

Aetna modified CPB 0714 covering inert gas rebreathing for cardiac output measurement and intra-cardiac shunt validation, effective November 27, 2025. Every claim tied to these procedures faces denial under Aetna's coverage policy.

Aetna, a CVS Health company, updated CPB 0714 to classify all three inert gas rebreathing procedures as experimental, investigational, or unproven. That designation is the hardest wall in payer policy — it means no medical necessity argument gets you past it. If your cardiology or pulmonology team has been billing for inert gas rebreathing in patients with pulmonary hypertension (ICD-10 I27.0 through I27.29) or intra-cardiac shunt diagnoses (Q21.0 through Q21.9), those claims are now on the denial track under CPB 0714 Aetna billing guidelines.

Quick-Reference Table

Aetna Inert Gas Rebreathing Coverage Criteria and Medical Necessity Requirements 2025

Here's the short version: there are no covered indications under this coverage policy. Aetna does not recognize inert gas rebreathing as meeting medical necessity for any of the three clinical applications addressed in CPB 0714.

The policy covers three specific procedures — measuring cardiac output via inert gas rebreathing, predicting survival in pulmonary hypertension patients, and validating intra-cardiac shunts. All three are classified as experimental, investigational, or unproven. That's not a soft exclusion you can argue around with clinical notes.

When Aetna uses the term "experimental, investigational, or unproven," it means the payer has concluded that sufficient evidence does not exist to establish effectiveness. Prior authorization won't save a claim here. Even a perfectly documented prior auth request runs into the same wall — the procedure itself is excluded, not just the process of getting approval for it.

This matters for your revenue cycle team because these diagnoses — particularly the pulmonary hypertension codes in the I27.x family — are high-acuity cases where clinical teams often pursue every available diagnostic tool. The Aetna inert gas rebreathing coverage policy draws a hard line regardless of clinical rationale.

If your physicians are ordering inert gas rebreathing for Aetna-insured patients and expect reimbursement, have that conversation with the ordering provider now. The effective date of November 27, 2025 is already past. Claims submitted after that date for these procedures are denial exposure on your AR.

Aetna Inert Gas Rebreathing Exclusions and Non-Covered Indications

All three procedures addressed in CPB 0714 carry the experimental designation. There is no partial coverage, no covered subset of patients, and no qualifying criteria that unlocks reimbursement.

Procedure 1: Cardiac output measurement via inert gas rebreathing. Aetna does not cover this as a diagnostic method for any indication. Alternative cardiac output monitoring methods — including electrical bioimpedance (addressed separately under CPB 0472) — may carry different coverage status. But inert gas rebreathing specifically is out.

Procedure 2: Survival prediction in pulmonary hypertension. Patients with pulmonary hypertension coded under I27.0 through I27.29 are directly addressed in this policy. The inert gas rebreathing approach to prognostication is not covered. This is a meaningful exclusion given how complex and resource-intensive pulmonary hypertension management is — and how often clinicians want additional prognostic data.

Procedure 3: Intra-cardiac shunt validation. This affects patients with congenital cardiac septal malformations coded under Q21.0 through Q21.9. Aetna excludes inert gas rebreathing as a shunt validation method. If your pediatric cardiology or congenital heart program uses this technique, flag those cases now.

The pattern here is consistent with how Aetna handles other non-invasive cardiac monitoring technologies — see CPB 0472 on electrical bioimpedance for context. When the evidence base for a newer diagnostic method doesn't meet Aetna's threshold, the experimental designation is applied broadly until the evidence changes.

Coverage Indications at a Glance

Aetna Inert Gas Rebreathing Billing Guidelines and Action Items 2025

The effective date of November 27, 2025 means this policy is already live. Here's what your billing team needs to do right now.

CPT, HCPCS, and ICD-10 Codes for Inert Gas Rebreathing Under CPB 0714

The policy data for CPB 0714 does not list specific CPT or HCPCS procedure codes. Aetna's policy addresses this technology by clinical description rather than by specific procedure codes. Your billing team should work with your coding staff and the ordering providers to identify which codes your facility uses to bill inert gas rebreathing procedures — then apply the experimental designation from CPB 0714 to those codes in your charge master and claim edits.

This is an important nuance. The absence of listed CPT codes does not mean the policy is ambiguous about coverage. The exclusion is explicit and technology-specific. If you're uncertain which codes apply to your billing mix, talk to your coding consultant before the effective date creates more denied claims.

Key ICD-10-CM Diagnosis Codes Under CPB 0714

These are the diagnosis codes Aetna associates with the procedures addressed in this policy. Claims with these diagnoses — where inert gas rebreathing is the procedure — fall under CPB 0714's experimental designation.

The full I27.x range covers the breadth of pulmonary hypertension subgroups, from primary pulmonary hypertension (I27.0) through secondary and other specified forms (I27.20–I27.29). The Q21.x range covers congenital septal malformations including ventricular septal defect, atrial septal defect, atrioventricular septal defect, and related conditions. Any claim combining one of these diagnosis codes with an inert gas rebreathing procedure is a claim denial waiting to happen under this policy.